There are 360 resources available
51P - Immunological analysis of blood from patients with solid tumors treated with TILT-123, an oncolytic adenovirus encoding for tumor necrosis factor alpha (TNFa) and interleukin 2 (IL-2)
Presenter: Santeri Pakola
Session: Poster Display
166P - Combination of 5-fluorouracil (FU), interferon (IFN)-alpha2, and nivolumab in unresectable fibrolamellar liver cancer
Presenter: sunyoung lee
Session: Poster Display
52P - MUC1 targeted immunotherapy with an oncolytic adenovirus coding for a bispecific T cell engager
Presenter: Saru Basnet
Session: Poster Display
53P - Combining cancer vaccines based on arenavirus vectors with 4-1BB (CD137) agonists enhances therapeutic efficacy in a non-inflamed tumor model
Presenter: Judith Strauss
Session: Poster Display
168P - Liver metastases (mets) and treatment effect of cemiplimab-based therapy: an analysis from three Phase 3 trials (EMPOWER-Lung 1, EMPOWER-Lung 3 Part 2, and EMPOWER-Cervical 1)
Presenter: Ana Baramidze
Session: Poster Display
54P - Oncolytic virus combined PD-1 antibody Toripalimab in advanced lung cancer with liver metastases: An Early Stage, Single Arm, Study (TROJAN 2201)
Presenter: jing Yang
Session: Poster Display
169P - Immunomodulatory effects of RBS2418, an oral ENPP1 inhibitor in combination with pembrolizumab in checkpoint-refractory metastatic adrenal cancer
Presenter: Jeffrey Glenn
Session: Poster Display
55P - Mutations Localized at the Membrane Predict Immunotherapeutic Efficacy in Cancer Treatment
Presenter: Zoe Goldberger
Session: Poster Display